Syngene International Ltd.

Discovery Chemistry, Discovery Biology, Integrated Drug Discovery

Process R&D, Custom manufacturing, formulation development, Clinical supplies, safety assessment

Syngene International Ltd. provides wide range of services which includes clinical supplies. It belongs to formulation development services category. It includes scale range - 0.1 kg to 50 kg, packaging - bottles and blister packing. Contact us for more information.

Syngene’s Antibody Drug Conjugate (ADC) unit brings together an array of multidisciplinary capabilities in antibody generation, linker and payload chemistry, conjugation chemistry, in vitro and in vivo oncology in an integrated platform.

Syngene’s Oligonucleotide capacity & services ranges from development to cGMP manufacturing of chemically synthesized high quality modified and non-modified custom Oligonucleotide (DNA/RNA), siRNA (single & double stranded, miRNA (modified and non-modified), Antisense, fast delivery of Oligonucleot...

Syngene International Ltd. provides wide range of services which includes acute, sub-chronic and chronic toxicity studies. It belongs to toxicology services category. It includes : acute toxicity studies, sub-acute toxicity studies, sub-chronic toxicity studies, chronic toxicity studies.

Syngene International Ltd. provides wide range of services which includes adme/dmpk. It belongs to biology services category. It includes : ADMET assays, PK studies, bioanalysis. Contact us for more information.

Syngene International Ltd. provides wide range of services which includes analytical characterization & quality control. It belongs to biologics development & manufacturing services category. It includes analytical method transfer or development followed by qualificationAnalytical method validation (ICH Q2...

Syngene International Ltd. provides wide range of services which includes analytical method development. It belongs to polymer research services category. It develops methods for molecular weight determination using an aqueous and non-aqueous system ensuring robust, reproducible and reliable data for all t...

Syngene International Ltd. provides wide range of services which includes analytical method development and validation. It belongs to formulation development services category. It includes analytical method development / analytical method validation: assay, purity, dissolution testing, forced degradation s...

Syngene International Ltd. provides wide range of services which includes antibody generation. It belongs to biology services category. It includes : polyclonal, generation of polyclonal antibodies – new zealand white rabbit standard or custom protocols, variety of antigens (bacterial, fusion proteins...

Syngene International Ltd. provides wide range of services which includes battery of genetic toxicology studies. It belongs to toxicology services category. It includes studies from 7-days to 6-months in duration, bacterial reverse mutation test (ames test), chromosome aberration test (in vitro) in cho cel...

AI helps identify better targets and candidates for drug development faster by utilising large datasets of biological and chemical information and applying machine learning algorithms to analyse the data.

TBC

Syngene revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 crores in the first quarter (1) Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24 
(2) US FDA approval for API manufacturing plant in Mangalore received 
(3) Acquisition of land in Hyderabad to support long term growth in research services

MINNEAPOLIS (GLOBE NEWSWIRE) July 17, 2023, Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced an Issue Notification for the Australian patent 2019213664 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid until 2039. 

In this Point of View, we discuss the role of biophysicsdriven analytical tools in accurately identifying biologics CQAs and analyzing HOS – resulting in the final product being efficacious and safe for patients from a regulatory perspective

Bangalore, July 04, 2023: Syngene (or the “Company”) today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 liters of installed biologics drug substance manufacturing capacity for Syngene. The site has the potential for future expansion up to a further 20,000 liters of biologics drug substance manufacturing capacity. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing. 

Read this white paper to gain insights about perceptions around integrated and standalone outsourcing. The white paper is based on surveys conducted across emerging biopharma, mid-size and large pharma in North America, Europe and other regions.

Bangalore, January 23, 2023: Syngene International Limited announced its third quarter results. Quarterly revenue was up to Rs. 803 crores, while profit after tax for the quarter increased to Rs 110 crores.

Syngene's Large Molecule Bio Analytical Laboratory is India’s premier GLP certified and GCLP compliant lab specializes in immunogenicity and pharmacokinetic (PK) analysis of biologics and biosimilars. The laboratory has extensive experience in working with monoclonal antibodies, recombinant proteins, enzymes, biomarkers, cytokines, vaccines and growth hormones during the early and late phases of the drug development (preclinical and clinical) process. We are having 14+ years of extensive experience in working across a wide variety of technologies and therapeutic areas. The state-of-the-art infrastructure comprises of well-equipped labs & world-class equipment, talented scientific teams, excellent regulatory track record, effective sample management processes, accuracy, data integrity, safety and quality. Read more at https://bit.ly/3fLCwLf

Bangalore, 14 July 2022, Syngene International Limited announced the signing of a 10- year agreement with leading animal health company, Zoetis, to manufacture the drug substance for Librela® (bedinvetmab), a first in class monoclonal antibody used for treating osteoarthritis in dogs. Launched in Europe, the UK and Switzerland, the product won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition. 

In this viewpoint, we discuss how Syngene can help you move your PROTAC programs from hit to lead to the clinic with speed.

In this viewpoint, we discuss the challenges in the detection and quantitation of process-related impurities including nitrosamine impurities and Syngene's capabilities and solutions to address them.

In this viewpoint, we discuss how to use technology to enhance productivity using a high seeding density (HSD) approach. The intensified process through converting the traditional fed-batch process to the HSD process could be the answer to increased upstream productivity. 

Syngene’s Sterile Fill-Finish facility is custom-built to meet market demand for small-scale, sterile drug products having short development timelines. Our facility offers Drug substance and Drug product development and manufacturing for both large and small molecules.

Syngene’s Analytical Development team is a leader in method development, method validation, method transfer, and application of analytical expertise to ensure the delivery of quality drug products for early as well as late-phase drug development programs. The team has expertise in developing phase-appropriate methods, validation, and transfer of the methods for drug substance and drug product (solid, semisolid, solutions, simple and complex long-acting parenteral formulations). Our team analyzes small molecules (RSMs, intermediates, and APIs), semi-large molecules (polymers, oligonucleotides), and biologics using a variety of spectroscopic, chromatographic, and physiochemical techniques. 

In continuation of our earlier video on ‘Life at Syngene,’ learn from our Research Director, Jayadeva Sajankila, Syngene’s unique capabilities in Solid-state chemistry and how Safety is at the heart of everything we do – personally and professionally. 

Visit us at www.syngeneintl.com

Watch this video on what our Research Director, Jayadeva Sajankila, has to say on what makes Syngene unique, new expectations driving drug development today, and more. Visit us at www.syngeneintl.com

Enabling quality-driven large-scale API manufacturing. State-of-the-art multi-product, multi-client contract manufacturing facility located at Mangalore Special Economic Zone (MSEZ) spread across a sprawling 46 acres campus. Plant designed to support large-scale API and advanced intermediate manufacturing. Offers large scale manufacturing capability in the range of 2 KL to 12.5 KL compliant with ICH Q7 (cGMP) guidelines. -For more information, contact us at [email protected] -Visit us at www.syngeneintl.com

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.#ContractResearch #CRO #CDMO #CMO #Syngene #Biopharma

Syngene’s clinical development services team enables early-phase to late-phase clinical trials required for drug development programs across a wide range of therapeutic areas.

Our services include clinical trial management, pharmacokinetic (PK) analysis and bioanalytical studies of small and large molecules, biometrics and clinical data management, and Syngene’s central lab services. We also provide regulatory services for all stages of drug development, medical monitoring services, pharmacovigilance solutions, and medical writing for clinical study documents.

Syngene offers formulation development services to help clients determine optimal dosage levels for therapeutic formulations in oral solid, liquid, and injectable forms. Our integrated services extend to new chemical entities (NCE), late-phase product development, and over-the-counter products with a focus on quality, speed, and cost-efficiency.Our strong scientific team has broad experience and expertise in collaborative practices with a global customer base for formulation development services and analytical support.We cater to pharmaceutical companies worldwide, providing extensive pre-formulation studies, toxicology formulation, formulation development, and analytical method development and validation. Our services include conducting stability studies as per the guidelines of The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and regulatory dossier preparation.

Syngene provides comprehensive process research and development services as well as current good manufacturing practices (cGMP) manufacturing capacities to help clients with investigational to commercial-scale development programs. We cater to several industries including pharmaceuticals, specialty chemicals, agrochemicals, polymers, oligonucleotides, animal health, and consumer products. Our team excels at resolving complex scientific problems with a systematic approach and in a time-bound manner while assuring the quality of all processes and products.Syngene’s development capabilities include Regulatory starting materials (RSMs), APIs, High Potency APIs, NCEs, Novel advanced intermediates and oligonucleotides with therapeutic and diagnostic applications, from laboratory to manufacturing scale of 100 g to 500 kg. Our expertise also includes working with performance chemicals and specialty materials using synthetic organic chemistry and polymer chemistry.

Syngene is an integrated research, development, and manufacturing services organization offering biologics solutions for human and animal health As a fully integrated custom biomanufacturer, our solutions include mammalian and microbial capabilities for clinical and commercial supply of drug substance and drug products

We have a strong track record in terms of both experience and know-how across mAbs, bispecific, ADC, antibody fragments, recombinant proteins, glycoproteins, mRNA, pDNA, microbial (E. coli and Pichia) and microbiome Live Biotherapeutic Product (LBP).